CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. Approved for actinic keratosis. First approved in 2020.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
CARBON DIOXIDE, USP is an inhalation gas approved in 2020 for actinic keratosis treatment, operating as an X-ray contrast agent through radiographic contrast activity. This product represents a non-traditional application of carbon dioxide gas in dermatologic care. It is administered via inhalation as a gaseous dosage form.
Product is in peak lifecycle stage with moderate competitive pressure (30), but limited commercial visibility with no reported spending data suggests a niche or specialty-focused positioning.
X-Ray Contrast Activity
Radiographic Contrast Agent
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CARBON DIOXIDE, USP currently shows zero linked job openings, reflecting a mature, stable product with limited immediate hiring. Career opportunities likely center on field-based sales, proceduralist support, and market access given the specialized procedure-driven nature of this therapy.